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ORIGINAL ARTICLE
Factors related to the experience of menopausal symptoms in women
prescribed tamoxifen
Zoe Moon, Myra S. Hunter, Rona Moss-Morris and Lyndsay Dawn Hughes
Health Psychology Section, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
ABSTRACT
Introduction: Menopausal symptoms are frequent and severe in breast cancer survivors taking
tamoxifen; however, treatment options are limited for these patients as hormonal replacement
therapy is contraindicated. This study aimed to explore the experience and attribution of meno-
pausal symptoms and identify factors related to the experience of menopausal symptoms in
women taking tamoxifen.
Methods: Women who had been prescribed tamoxifen for a diagnosis of primary breast cancer
were recruited from oncology clinics across England and from online advertisements. Seven hun-
dred and forty women completed questionnaires assessing illness perceptions, social support,
mood and symptom duration/severity.
Results: Eighty-four percent of women had experienced hot flushes and 80% experienced night
sweats; of these, 60% experienced severe symptoms. Symptoms persisted throughout 5 years of
treatment and were mainly attributed to tamoxifen. Logistic regressions showed that depressive
symptoms, previous chemotherapy and being employed were associated with increased odds of
hot flush or night sweat prevalence. Symptom severity was associated with depression, being
employed and attributing symptoms to tamoxifen.
Discussion: These findings have clinical implications in terms of targeting women who are more
at risk and offering non-hormonal treatment options, such as cognitive behavioural therapy, to
help women to develop self-management strategies for coping with menopausal symptoms.
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Introduction
Hot flushes and night sweats (HFNS), the main symp-
tom of the menopause, typically involve a sudden sen-
sation of heat and warmth, accompanied by
reddening of the skin and sweating. They are thought
to result from disturbances of the temperature regulat-
ing mechanism in the hypothalamus, triggered by
reduced oestrogen levels [1]. Whilst HFNS can vary sig-
nificantly between individuals, women with breast can-
cer are five times more likely than age matched
controls to experience these symptoms and are also
more likely to experience longer, more frequent and
more severe HFNS [2–4]. Women who take tamoxifen
are twice as likely to experience HFNS [2] and more
likely to report severe to intolerable HFNS [5] than
other breast cancer survivors.
Tamoxifen, or a similar class of drugs (aromatase
inhibitors), are prescribed to up to three quarters of
breast cancer survivors in order to reduce the risk of
recurrence [6]. They are prescribed to women with
oestrogen receptor positive breast cancer and work by
blocking the effects of oestrogen on cancer cells.
Tamoxifen is prescribed mainly to pre-menopausal
women, whereas aromatase inhibitors are prescribed
only in post-menopausal women. Recent evidence
suggests that survival benefits are enhanced if tamoxi-
fen is taken for an additional 5 years [7,8]. This
increase in treatment duration, accompanied by a rise
in breast cancer survival rates, means that increasing
numbers of women may be suffering from HFNS as a
consequence of tamoxifen. Studies have indicated that
HFNS prevalence in breast cancer survivors may be as
high as 80% [9–11]. Tamoxifen is associated with a
range of other side effects including weight gain,
insomnia, joint pain and vaginal dryness [12,13]. Whilst
not life threatening, these symptoms can have a con-
siderable impact on quality of life [11]. HFNS in breast
cancer survivors are associated with anxiety, sleep
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problems, poor emotional functioning [10] and poor
physical health [14]. Furthermore, these symptoms can
undermine adherence to tamoxifen [15,16].
One of the key treatments for HFNS, hormone
replacement therapy (HRT) [17], is contraindicated in
breast cancer survivors due to a potential increased
risk of cancer recurrence, which severely limits treat-
ment options for HFNS in these patients. There are
some non-hormonal options, such as venlafaxine or
gabapentin [18], but many breast cancer survivors are
keen to avoid additional medications which likely have
side effects [10]. Several recent papers have called
attention to the lack of research into HFNS in breast
cancer survivors [1,19] and highlighted a need to
understand the experiences of these women, with a
view to identifying safe and effective treatments
[10,19,20].
Factors associated with HFNS in the general popula-
tion include lower levels of education [21,22], African
American race [23,24], younger age [25] and being
without a partner [26,27]. The cognitive model of
HFNS explains how the perception, attribution and
appraisal of menopausal symptoms are influenced by
cognitive factors, beliefs and mood [28]. For example,
stress or negative affect can reduce the threshold for
detection of physical sensations, and increase the like-
lihood that women will attend to, and therefore
report, HFNS [28,29]. Anxiety has been shown to pre-
cede hot flushes [30]; however, studies suggest that
there is a complex bi-directional relationship between
HFNS and depression whereby HFNS can cause
depressed mood, but may also be a result of depres-
sion [1,28,31].
Moreover, anxiety and depression are associated
with negative beliefs, which in turn affect cognitive
appraisal of symptoms [28]. For example, negative
thoughts such as embarrassment, disgust and worry
are linked to more problematic hot flushes [32]. The
common sense model of illness representations posits
that how patients represent symptoms and where
they attribute them will likely guide how they cope
with the symptom [33]. This may influence emotional
reactions, illness outcomes and health behaviours such
as treatment adherence or help seeking [34–37]. The
cognitive model of HFNS has informed the develop-
ment of cognitive behavioural therapy (CBT) for HFNS,
which has been shown to reduce the impact of HFNS
[38,39].
Whilst the cognitive model of HFNS is well
accepted in the general population [1,40], the
experience of menopausal symptoms in women tak-
ing tamoxifen remains under-researched. This is
important considering the increasing rates of breast
cancer, partnered with greater survivorship and
increased duration of tamoxifen treatment. This
paper aimed to explore the experience and attribu-
tion of menopausal symptoms in women prescribed
tamoxifen and, using the cognitive model and other
sociodemographic predictors, identify factors related
to the experience of HFNS.
Methods
The study was approved by the Northampton National
Research Ethics Committee (Ref.: 14/EM/1207), with
site specific approvals for each site.
Participants and procedure
Participants were recruited through oncology clinics in
27 NHS Trusts across England and through advertise-
ments on Facebook groups, Twitter and charity web-
sites between April 2015 and October 2015. To be
eligible for the study, patients had to be female, over
18, have a diagnosis of primary breast cancer and cur-
rently being prescribed tamoxifen. Women were
screened in clinic and those who were eligible were
invited to participate in the study either in the clinic
or with a postal invitation. Women who replied to the
online advert were screened by the researcher.
Informed consent was taken from all participants. The
questionnaire took approximately 15–20min to com-
plete; participants could complete it in clinic or online,
or take it away and return it to the researcher using a
stamped addressed envelope. This formed part of a
larger study investigating adherence to tamoxifen.
Only measures relevant to this study are reported
here.
Measures
Experience of menopausal symptoms
Participants were asked to indicate whether they had
experienced symptoms using the identity scale from
the Revised Illness Perceptions Questionnaire (IPQ-R
[41]). This included the core symptoms from the IPQ-R
as well as additional symptoms such as HFNS.
Participants indicated whether they attributed symp-
toms to their breast cancer, their tamoxifen treatment
or to previous cancer treatment. The additional con-
cerns subscale from the FACT-ES [42] was used to
measure the experience and severity of side effects.
The FACT-ES is a quality of life scale for breast cancer
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patients taking endocrine therapy, with good internal
consistency and test–retest reliability [42]. Participants
rated symptom severity on five-point scales, from “not
at all” to “very much”.
Potential predictors
Women were asked to provide sociodemographic data
including their date of birth, age they left full-time
education, relationship status, employment status,
menopausal status (at diagnosis), date first prescribed
tamoxifen and previous chemotherapy. Menopausal
status was defined as pre-menopausal, menopausal or
post-menopausal.
Mood
The Hospital Anxiety and Depression Scale (HADS [43])
was used to measure depression and anxiety. Each
item is scored on a scale of 0–3, with higher scores
reflecting higher levels of depression and anxiety. The
scale has good internal consistency in patients with
breast cancer [44,45].
Social support
The Multidimensional Scale of Perceived Social
Support [46] was used to measure perceived social
support. The scale has demonstrated good internal
and test–retest reliability [46] and has been used suc-
cessfully to measure social support in patients with
breast cancer [47,48].
Statistical analysis
Statistical analyses were performed using SPSS v21
(SPSS Inc., Chicago, IL). For analysis of symptom preva-
lence, women were coded as experiencing a symptom
if they had selected answers on the FACT-ES from a lit-
tle bit to very much. For analysis of symptom severity,
women who scored either of the top two answers
(quite a bit/very much) were coded as experiencing
severe symptoms and were compared to women expe-
riencing mild to moderate symptoms (a little bit/some-
what). The attribution of symptoms was analysed
using responses on the IPQ-R. Univariate logistic
regressions were calculated to assess the relationships
between predictor variables and HFNS prevalence.
Predictor variables were chosen based on the cogni-
tive model and previous literature identifying sociode-
mographic variables which may be related to HFNS.
Variables tested in univariate analysis were age, ethni-
city, age left full time education, relationship status,
employment status, menopausal status (at diagnosis),
chemotherapy, months since first prescribed tamoxi-
fen, anxiety, depression, social support and whether
symptoms were attributed to tamoxifen. Months since
first tamoxifen prescription, social support and depres-
sion were skewed and log transformations were per-
formed. Variables which showed a significant
relationship in univariate analysis were entered into a
final multivariate model. Categorical variables such as
ethnicity were converted into dichotomous dummy
coded variables. The same analysis was then con-
ducted to predict experience of severe HFNS in sub-
group analyses of participants who had experienced
these symptoms.
Results
Participant rate
One thousand two hundred and twenty-eight women
were posted information about the study or
approached in clinic. Seven hundred and forty-six
women from 27 centres across England returned the
questionnaire, giving a response rate of 61%. An add-
itional six questionnaires were received from a site
with no response rate information. Sixty-one women
were recruited online. Once women who had reported
discontinuing tamoxifen were removed (n¼ 73), the
sample consisted of 740 women.
Table 1. Demographics of study population.
N (%)
Age, mean (SD) 53 (10)
Range 30–90
Ethnicity
White British 681 (92%)
Mixed/multiple ethnic 7 (1%)
Asian/Asian British 30 (4%)
Black/Black British 12 (2%)
Other ethnic background 10 (1%)
Relationship status
Single 791 (11%)
Married 431 (58%)
Widowed 34 (5%)
Separated/divorced 91 (12%)
Co-habiting 102 (14%)
Employment status
Employed full time 281 (38%)
Employed part time 204 (28%)
Homemaker 52 (7%)
Unemployed 57 (8%)
Retired 114 (15%)
Other 30 (4%)
Age left full time education
Under 18 366 (49%)
Over 18 376 (51%)
Menopausal status at diagnosis
Pre-menopausal 405 (55%)
Peri-menopausal 83 (11%)
Post-menopausal 202 (27%)
Unsure/missing 50 (7%)
Months since prescribed tamoxifen, mean (SD) 19.5 (18.3)
Range 0.2–121
Received chemotherapy 381 (52%)
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Sample characteristics
The mean age was 53 (SD¼10, range 30–90) (Table 1).
Women were diagnosed with stage I to stage III breast
cancer and were prescribed tamoxifen. The majority of
participants were married/cohabiting (72%) and were
employed (66%). Forty-nine percent left full time edu-
cation under the age of 18. Over half of women were
pre-menopausal at diagnosis (55%) and had been
treated with chemotherapy (52%). Women had been
taking tamoxifen for on average 20 months (SD¼ 18,
range 0.2 months to 10 years).
Experience, attribution and duration of menopausal
symptoms
A high percentage of participants had experienced hot
flushes (84%) and/or night sweats (80%) and around
60% of these had experienced severe HFNS (Table 2).
Patients also self-reported experiencing the following
symptoms from the FACT-ES; fatigue (53%), weight
gain (66%), mood swings (67%), loss of libido (68%),
vaginal dryness/discharge/itchiness (72%) and joint
pain (72%). All symptoms were attributed to tamoxifen
more often than to breast cancer or previous cancer
treatment. The symptoms most commonly attributed
to tamoxifen on the IPQ-R were hot flushes (66%),
night sweats (54%), weight loss/gain (40%), joint pain
(37%), fatigue (35%), sleep difficulties (34%), vaginal
dryness/discharge/itchiness (34%) and change in sex
drive (27%). Figure 1 shows that the prevalence of
HFNS is high across participants at different time
points of treatment, including those in their fifth year.
In separate analyses of those who had experienced
symptoms (n¼ 623 for HF/n¼ 587 for NS), the
Table 2. Experience and attribution of symptoms.
FACT-ES IPQ-R
% Experienced in
past seven days
% With moderate to
severe symptoms
% Attributed to
breast cancer
% Attributed to previous
breast cancer treatment
% Attributed to tamoxi-
fen treatment
Hot flushes 84 64 9 8 66
Night sweats 80 60 7 7 54
Change in sex drivea 40 – 17 8 27
Loss of sex drive 68 46 – – –
Pain or discomfort with
intercourse
41 40 – – –
Vaginal discharge/
dryness/itchiness
72 39 5 5 34
Weight gain 66 46
Weight loss/gaina 47 – 10 10 40
Feeling downa 37 – 18 8 20
Mood swings 67 30 – –
Fatiguea 53 – 19 13 35
Sleep difficultiesa 44 – 13 9 34
Joint pain 72 55 6 14 37
Headaches 53 21 3 8 15
Loss of concentrationa 38 – 12 9 24
Not all women who reported a symptom will have reported how they attributed it, and women could select multiple sources of attribution. % with mod-
erate to severe symptoms in separate analysis of only those who experienced symptom.
aThese symptoms are not included in the FACT-ES and prevalence is derived from the IPQ-R.
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Figure 1. Percentage of women taking tamoxifen who reported hot flushes or night sweats.
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proportion of women experiencing severe symptoms
remains relatively high across the 5 years, but begins
to decrease slightly at 4 years of treatment (Figure 2).
Factors related to prevalence of HFNS
In the univariate analysis, younger age (OR¼ 0.95, 95%
CI¼ 0.93–0.97), being employed (OR¼ 3.74, 95%
CI¼ 2.45–5.72), being premenopausal at diagnosis
(OR¼ 1.95, 95% CI¼ 1.29–2.94), receiving chemother-
apy (OR¼ 3.13, 95% CI¼ 2.04–4.80) and having higher
levels of anxiety (OR¼ 1.09, 95% CI¼1.04–1.15) and
depression (OR¼ 1.90, 95% CI¼ 1.24–2.90) were signifi-
cantly related to hot flush experience (Table 3). These
variables were entered into a logistic regression
model, which explained 15% of the total variance
(Nagelkerke R2). Women who were employed
(OR¼ 2.65, 95% CI¼ 1.44–4.90), who scored higher on
the HADS depression scale (OR¼ 2.22, 95%
CI¼ 1.33–3.70) and who had chemotherapy (OR¼ 1.93,
95% CI¼ 1.14–3.26) were around twice as likely to
experience hot flushes (Table 4).
In the univariate analysis (Table 3), experience of
night sweats was related to younger age (OR¼ 0.97,
95% CI¼ 0.95–0.98), being employed (OR¼ 2.41, 95%
CI¼ 1.63–3.56), being premenopausal (OR¼ 1.46, 95%
CI¼ 1.00–2.11), being without a partner (OR¼ 0.63,
95% CI¼ 0.43–0.92), receiving chemotherapy
(OR¼ 1.91, 95% CI¼ 1.32–2.74) and higher levels of
anxiety (OR¼ 1.11, 95% CI¼ 1.06–1.16) and depression
(OR¼ 2.42, 95% CI¼ 1.51–3.32). These variables were
entered into a logistic regression model which
accounted for 12% of the total variance; women with
more depressive symptoms (OR¼ 2.41, 95%
CI¼ 1.34–4.33) and who were employed (OR¼ 2.18.
95% CI¼ 1.24–3.82) were more likely to experience
night sweats (Table 4).
Factors related to severity of HFNS
In the univariate analysis of those who experienced
hot flushes (n¼ 623), hot flush severity was associated
with being employed (OR¼ 1.62, 95% CI¼ 1.07–2.43),
premenopausal (OR¼ 1.52, 95% CI¼ 1.07–2.14), having
chemotherapy (OR¼ 1.56, 95% CI¼ 1.12–2.17), higher
levels of anxiety (OR¼ 1.07, 95% CI¼ 1.03–1.11) and
depression (OR¼ 2.04, 95% CI¼ 1.45–2.87) and attrib-
uting hot flushes to tamoxifen (OR¼ 2.58, 95%
CI¼ 1.77–3.77) (Table 5). Variables were entered into a
final model which explained 18% of the variance in
hot flush severity (Table 4). Women who attributed
their hot flushes to tamoxifen were almost four times
more likely to experience more severe hot flushes
(OR¼ 3.78, 95% CI¼ 2.43–5.77) and women who had
more depressive symptoms (OR¼ 1.99, 95%
CI¼ 1.22–3.24) or were employed (OR¼ 1.68, 95%
CI¼ 1.03–2.73) were almost twice as likely to experi-
ence severe hot flushes.
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Figure 2. Percentage of women taking tamoxifen who reported severe hot flushes or night sweats.
Table 3. Univariate regressions predicting prevalence of
HFNS.
Hot flushes Night sweats
OR 95% CI OR 95% CI
Age 0.95 0.93–0.97 0.97 0.95–0.98
Ethnicity
Other versus White British 1.18 0.68–2.06 1.16 0.70–1.92
Age left full time education
<18 versus 18þ 1.05 0.71–1.55 1.00 0.70–1.42
Employment status
Employed versus not employed 3.74 2.45–5.72 2.41 1.63–3.56
Marital status
No partner versus partner 0.80 0.52–1.23 0.63 0.43–0.92
Menopausal status
Pre- versus post-menopausal 1.95 1.29–2.94 1.46 1.00–2.11
Chemotherapy 3.13 2.04–4.80 1.91 1.32–2.74
Months since prescribed 1.10 0.99–2.23 1.03 0.94–1.13
HADS anxiety 1.09 1.04–1.15 1.11 1.06–1.16
HADS depression 1.90 1.24–2.90 2.42 1.51–3.32
Social support 1.35 0.97–1.89 1.15 0.85–1.54
p< (0).001.p< 0.05.
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In the univariate analysis of participants who experi-
enced night sweats (n¼ 587), anxiety (OR¼ 1.06, 95%
CI¼ 1.02–1.11), depression (OR¼ 2.03, 95%
CI¼ 1.46–2.83) and attribution of night sweats to tam-
oxifen (OR¼ 2.63, 95% CI¼ 1.84–3.74) were related to
night sweat severity. All variables except anxiety
remained significant in the multivariate analysis,
accounting for 11% of the total variance (Table 4).
Attributing night sweats to tamoxifen (OR¼ 2.80, 95%
CI¼ 1.94–4.01) and depression (OR¼ 1.10, 95%
CI¼ 1.03–1.17) were both linked to increased odds of
severe night sweats.
Discussion
This paper examined the experience of menopausal
symptoms in breast cancer survivors taking tamoxifen
and explored factors contributing to the experience of
HFNS. Results showed that 84% of women had experi-
enced hot flushes and 80% had experienced night
sweats. This is consistent with previous research in the
community indicating a prevalence of around 80%
[9–11], but is much higher than the prevalence of
29–45% found in several large RCTs comparing tam-
oxifen with aromatase inhibitors [49]. This may be
because some women who experienced negative side
effects discontinued treatment and were removed
from the RCTs. However, previously, less was known
regarding the severity of HFNS in women taking tam-
oxifen [50]. This paper adds new information, by show-
ing that around 60% of women experiencing HFNS
reported severe symptoms. The extent and severity of
these symptoms reinforces the need to identify who is
more at risk and to find ways to help patients manage
these symptoms [1,19,20]. Participants also reported
high levels of joint pain, vaginal discharge/dryness/
itchiness, loss of libido, mood swings and weight gain.
The prevalence of fatigue and sleep problems was
slightly lower than previously reported in patients tak-
ing tamoxifen [13,51], but loss of libido, vaginal symp-
toms and mood swings were higher than previous
reports have indicated [13,52,53]. Again, all symptoms
were reported at a greater frequency than found in a
review of RCTs [49].
Previous studies have suggested that HFNS are less
problematic after one year of tamoxifen treatment
[54,55] and patients are often advised that their symp-
toms will reduce after a few months. However, this
study shows that the prevalence of HFNS remains sta-
ble (around 80%) regardless of whether the patient is
in her first or fifth year of treatment. The severity of
symptoms also remains high up until the fourth year
of treatment. This highlights the need to identify
effective strategies to help women to manage their
HFNS across the duration of treatment. CBT has been
shown to reduce HFNS frequency and problem rating
in breast cancer survivors and can teach women long-
term self-management strategies [38,39,56].
Up to two-thirds of participants attributed HFNS to
tamoxifen. Participants also associated other symptoms
to tamoxifen, including fatigue, sleep difficulties, joint
pain, vaginal discharge/dryness/itchiness and weight
loss/gain. These symptoms are established side effects
of tamoxifen [13]. Women who attributed HFNS to
tamoxifen were three to four times more likely to
experience severe symptoms than those who did not
attribute their symptoms to tamoxifen. More research
is needed to confirm the direction of this effect and to
Table 4. Multivariate regressions predicting prevalence/severity of HFNS.
Hot flushes
prevalence
Night sweat
prevalence Hot flush severity Night sweat severity
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Employment status (employed versus not employed) 2.65 1.44–4.90 2.18 1.24–3.82 1.68 1.03–2.73
Chemotherapy 1.93 1.14–3.26
HADS depression 2.22 1.33–3.70 2.41 1.34–4.33 1.99 1.22–3.24 1.10 1.03–1.17
Attributing HF/NS to tamoxifen 3.78 2.43–5.77 2.80 1.94–4.01
p< 0.001.p< 0.05.
Table 5. Univariate regressions predicting severity of hot
flushes (n¼ 623) and night sweats (n¼ 587).
Hot flushes Night sweats
OR 95% CI OR 95% CI
Age 0.98 0.97–1.00 0.98 0.97–1.00
Ethnicity
Other versus white British 1.24 0.77–1.99 1.39 0.86–2.24
Age left full time education
<18 versus 18þ 1.07 0.77–1.48 1.28 0.92–1.78
Employment status
Employed versus not employed 1.62 1.07–2.43 1.23 0.81–1.87
Marital status
No partner versus partner 0.87 0.60–1.25 0.86 0.59–1.25
Menopausal status
Pre versus post-menopausal 1.52 1.07–2.14 1.31 0.92–1.85
Chemotherapy 1.56 1.12–2.17 1.06 0.76–1.47
Months since prescribed 1.02 0.94–1.12 1.00 0.92–1.09
HADS anxiety 1.07 1.03–1.11 1.06 1.02–1.11
HADS depression 2.04 1.45–2.87 2.03 1.46–2.83
Social support 1.56 0.93–2.62 1.14 0.69–1.91
Symptom attributed to tamoxifen 2.58 1.77–3.77 2.63 1.84–3.74
p< 0.001.p< 0.05.
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establish the consequences of attributing symptoms to
tamoxifen treatment. Previous studies have suggested
that symptom attribution is likely to affect coping
behaviours [33], but this was not tested in the current
study.
After controlling for demographic factors and
mood, women who had chemotherapy were twice as
likely to report hot flushes than women who had not
had chemotherapy. This conflicts with previous studies
in breast cancer patients, showing no association
between HFNS and chemotherapy [11,57]. However,
previous studies included mainly postmenopausal
women, and the association between chemotherapy
and HFNS may be stronger in premenopausal women
[58]. Chemotherapy can induce an early menopause in
some patients, increasing the incidence of HFNS [59],
which could explain the increased HFNS in premeno-
pausal women who have received chemotherapy.
Women who were employed were twice as likely to
experience HFNS and more likely to experience severe
hot flushes. This has important implications for sup-
porting women in the workplace. Studies have shown
that menopausal symptoms cause difficulty at work
and may impact negatively on work performance
[1,60,61]. Working women have discussed fears around
embarrassment and others’ reactions [62], which is
likely to exacerbate the severity of hot flushes. CBT
may be helpful to moderate negative thoughts around
menopausal symptoms in the workplace and to reduce
anxiety around stigma.
Higher scores on the depression scale were associ-
ated with twofold increased odds of HFNS incidence
and increased odds of severe HFNS. This supports the
cognitive model of HFNS [28], which proposes that
depressed mood can affect how patients perceive and
appraise their symptoms. However, it is likely that
there is a bi-directional relationship between HFNS
and depression, and it is unclear in this study if the
depressed mood is a result of the HFNS or if it is
increasing the likelihood that women will report symp-
toms. Anxiety was associated with increased odds of
HFNS in the univariate analysis, but was not significant
after controlling for other variables. This contrasts with
previous studies showing a clear relationship between
anxiety and hot flushes [30]. However, the lack of rela-
tionship between anxiety and HFNS has been shown
previously in breast cancer patients [63].
Age was significantly related to HFNS prevalence in
the univariate analysis, but was not significant in the
multivariate analysis. This is likely due to shared vari-
ance between age and menopausal status at diagno-
sis. Younger age has been found to be associated with
increased risk of hot flushes in breast cancer survivors
[5]; however, this effect has not been consistently
shown [11,13]. Previous studies have shown that
ethnicity is related to hot flush frequency [64].
African-American women tend to report more hot
flushes than Caucasian women and Japanese women
have been shown to report fewer symptoms
[24,65,66]. However, these effects are not always
shown [67] and the current study found no effect of
ethnicity on HFNS prevalence or severity. This may be
due to the lack of ethnic diversity in the study; only
8% of women self-identified as not White British.
Overall, the results suggest that a high proportion
of women experience symptoms such as HFNS as well
as fatigue, joint pain and vaginal symptoms. These
symptoms are often severe and women report experi-
encing them even in their fifth year of treatment. As
HRT is contraindicated, only 21% of breast cancer sur-
vivors receive any treatment for these symptoms [11]
and there is a need to identify non-hormonal treat-
ments. The North American Menopause Society
(NAMS) has reviewed evidence for non-hormonal treat-
ments and has found some degree of efficacy for
selective serotonin reuptake inhibitors in menopausal
women [68], but results are not conclusive and breast
cancer survivors have expressed a preference for non-
medical treatments [10]. CBT, which is based on the
cognitive model of HFNS, is recommended by NAMS
[69] and The National Institute for Health and Care
Excellence [17]. CBT has been shown to improve HFNS
problem rating and may provide patients with long
lasting self-management strategies. There is a need to
identify patients who are taking tamoxifen and have
received chemotherapy, as they may be more at risk
of hot flushes. Furthermore, the results stress a need
to support women who have returned to work follow-
ing breast cancer.
The strengths of this study were the large sample
size, use of validated measures and good response
rate. This is one of the largest samples used to investi-
gate the experience of HFNS in women taking tamoxi-
fen. However, that we measured symptom severity
and not bother is a limitation of this study. Measuring
perceived bother from symptoms as opposed to the
severity may provide a more thorough understanding
of the impairment associated with these symptoms
[66]. An additional limitation was the use of cross-
sectional data which prohibits causal assumptions for
some effects, such as the relationship between hot
flushes and depression. All measurements were sub-
jective; therefore, the hot flush frequency may be
more of an assessment of how people perceive their
symptoms rather than an objective physiological
measure. Data were not collected on use of additional
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medications. Some women may be prescribed anti-
depressants to manage their HFNS, and this could
have impacted on their mood. A final limitation with
the study was the lack of a comparison group, such as
breast cancer patients not receiving endocrine therapy,
with whom to compare the results to.
Conclusion
Prevalence and severity of HFNS, as well as other
symptoms such as vaginal dryness and joint pain, are
high in breast cancer survivors taking tamoxifen. There
is a need to identify non-hormonal treatment options
such as CBT to help support patients with these symp-
toms, especially as they persist for longer than previ-
ously believed. Furthermore, this study shows that
women who are in employment, received chemother-
apy, attribute HFNS to tamoxifen and have high
depression scores may require more targeted support
to manage HFNS.
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 Current knowledge on this subject
 Hot flushes and night sweats (HFNS) are common and severe in breast cancer survivors taking tamoxifen,
yet HFNS treatment options for these patients are limited.
 Sociodemographic and psychological factors have been shown to be related to HFNS in the general
population.
 Little is known about the experience of HFNS in breast cancer survivors taking tamoxifen, and few predic-
tors of HFNS have been found.
What this study adds
 Over 80% of women taking tamoxifen report experiencing HFNS, and around 60% of these women report
severe symptoms.
 Symptoms are mainly attributed to tamoxifen and the prevalence remains high even in the fourth and fifth
years of treatment, challenging previous research suggesting that HFNS would lessen after the first year of
treatment.
 Previous chemotherapy, higher levels of depression, being employed and attributing symptoms to tamoxi-
fen are related to HFNS prevalence/severity in breast cancer survivors taking tamoxifen.
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